Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

Recruiting now · Phase 4

Conditions studied: Chronic Kidney Diseases

In brief

The aim of this study is to observe the mechanisms of dapagliflozin on the renal interstitial tissue and renal perfusion. For this purpose, renal transplanted patients as an excellent model of CKD and high cardiovascular risk (similar to patients in DAPA-CKD study) are included in this study. The objectives of the study are to analyze the effects of dapagliflozin on renal morphology and renal perfusion in patients with impaired renal function one year after kidney transplantation. This is a randomized (1:1), single centre clinical study. Each patient will be randomly assigned in an unblinded fashion to 10 mg Dapagliflozin or not 9 months after transplantation. At least 48 patients will be randomized and included. The routine renal biopsy taken one year after kidney transplantation will allow us to determine the morphological integrity of peritubular fibroblasts, interstitial inflammatory cell density and investigate markers of inflammation, oxidative stress and nitic oxide synthase expression (iNOS).

Key facts

Study ID

NCT06560801

Run by

University of Erlangen-Nürnberg Medical School

People needed

48

Starts

2023-07-28

Expected to finish

2026-12-31

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Female and male patients aged between 18 and 75 years
• Patients with renal transplant having a stable eGFR, who are in stable condition, 9 months after transplantation, irrespective of their diabetes status
• Females of child bearing potential must be using adequate contraceptive precautions
• Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit
• Informed consent (§ 40 Abs. 1 Satz 3 Punkt 3 AMG) has to be given in written form

You may not qualify if…

• Type 1 diabetes mellitus.
• HbA1c > 10%
• Use of SGLT-2 inhibitor within the past 2 months
• Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 3 months prior to study inclusion.
• eGFR <25 ml/min/1.73m² (CKD-EPI Formula).
• Uncontrolled arterial hypertension (RR > 180/110 mmHg).
• Congestive heart failure (CHF) NYHA stage IV.
• Recurrent urinary tract infections (bacterial or fungal)
• Severe disorders of the gastrointestinal tract or other diseases which interfere the pharmacodynamics and pharmacokinetics of the drug.
• Significant laboratory abnormalities such as SGOT or SGPT levels more than 5 x above the upper limit of normal range.
• Antihypertensives are allowed but should be kept stable throughout the study period.
• Statins and other antihyperlipidemic drugs are allowed but should be kept stable throughout the study period.
• Drug or alcohol abusus
• Pregnant or breast-feeding patients
• Patients with contraindications to MRI

Where it is running

• Clinical Research Center (CRC) — Erlangen, Bavaria, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.